These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19231149)

  • 1. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.
    Knauf JA; Fagin JA
    Curr Opin Cell Biol; 2009 Apr; 21(2):296-303. PubMed ID: 19231149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
    Ciampi R; Knauf JA; Kerler R; Gandhi M; Zhu Z; Nikiforova MN; Rabes HM; Fagin JA; Nikiforov YE
    J Clin Invest; 2005 Jan; 115(1):94-101. PubMed ID: 15630448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
    J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p27 expression through RAS-->BRAF-->MAP kinase-dependent pathway in human thyroid carcinomas.
    Motti ML; De Marco C; Califano D; De Gisi S; Malanga D; Troncone G; Persico A; Losito S; Fabiani F; Santoro M; Chiappetta G; Fusco A; Viglietto G
    Cell Cycle; 2007 Nov; 6(22):2817-25. PubMed ID: 18032931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of B-Raf(V600E) cancers by MAPK hyper-activation.
    Atiq R; Hertz R; Eldad S; Smeir E; Bar-Tana J
    Oncotarget; 2016 Apr; 7(14):18694-704. PubMed ID: 26959890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intracellular signaling mechanisms in thyroid cancer].
    Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
    Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of cancers derived from thyroid follicular cells.
    Fagin JA; Krishnamoorthy GP; Landa I
    Nat Rev Cancer; 2023 Sep; 23(9):631-650. PubMed ID: 37438605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
    Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
    Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
    Namba H; Nakashima M; Hayashi T; Hayashida N; Maeda S; Rogounovitch TI; Ohtsuru A; Saenko VA; Kanematsu T; Yamashita S
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4393-7. PubMed ID: 12970315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAF inhibitors that evade paradoxical MAPK pathway activation.
    Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G
    Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression.
    Kondo T; Zheng L; Liu W; Kurebayashi J; Asa SL; Ezzat S
    Cancer Res; 2007 Jun; 67(11):5461-70. PubMed ID: 17545628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
    Smalley KS
    Int J Cancer; 2003 May; 104(5):527-32. PubMed ID: 12594806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
    Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
    Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).
    Leonardi GC; Candido S; Carbone M; Raiti F; Colaianni V; Garozzo S; Cinà D; McCubrey JA; Libra M
    Mol Med Rep; 2012 Oct; 6(4):687-94. PubMed ID: 22858857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.